Novartis AG ADR (NVS)vsSyndax Pharmaceuticals Inc (SNDX)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
SNDX
Syndax Pharmaceuticals Inc
$9.54
-0.52%
HEALTHCARE · Cap: $863.37M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 19703% more annual revenue ($57.36B vs $289.68M). NVS leads profitability with a 17.5% profit margin vs -72.3%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
SNDX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Intrinsic value data unavailable for SNDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Revenue surging 81.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -189.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : SNDX
The strongest argument for SNDX centers on Revenue Growth, Debt/Equity. Revenue growth of 81.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : SNDX
The primary concerns for SNDX are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while SNDX is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
SNDX is growing revenue faster at 81.6% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 33/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Syndax Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?